REG - SkinBioTherapeutics - Directorate change

SkinbiotherapeuticsAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260105:nRSE5534Na&default-theme=true

RNS Number : 5534N  SkinBioTherapeutics PLC  05 January 2026

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

 

Directorate Changes

 

5 January 2026 - SkinBioTherapeutics, (AIM: SBTX), a life science company
focused on skin health, announces the appointment of Alyson Levett as new
non-executive director and Chair of the Audit Committee and the promotion of
Emily Bertram to Chief Financial Officer and also to the Board. Danielle
Bekker has stepped down from the Board but will continue to support as an
external advisor effective from 31 December 2025. The appointments came into
effect from 1 January 2026.

 

Alyson Levett, Non-Executive Director and Chair of Audit Committee

Alyson Levett is a highly experienced non-executive Director and Chair of
Audit & Risk Committees. She has worked in a broad range of sectors
including FMCG, food manufacturing, engineering and technology, with proven
expertise with AIM companies and a wealth of shareholder and other stakeholder
engagement and relationship experience. She has over 20 years C suite
financial experience, culminating in being CFO at the strategy software
company, i-nexus where she stayed for a decade taking it onto AIM in a
successful IPO in 2018. She left to develop a portfolio Non-Executive career,
focussing on the role of Chair of the Audit Committee or Audit & Risk
Committee. Her current directorships are listed below, but include GETECH
Group plc, Eleco plc and the Financial Services Compensation Scheme. She also
acts as a Trustee on the charitable trust,  En-Fold Autism Support, and is a
volunteer advisor at The Cranfield Trust. She read Economics at Cambridge
University and is a qualified Chartered accountant (ICAEW).

 

Emily Bertram, Chief Financial Officer and Executive Officer to the Board

Emily Bertram has been promoted from Group Finance Director to Chief Financial
Officer and has become an executive Director on the Board of
SkinBioTherapeutics, following the AGM. Emily is an experienced certified
Chartered Accountant (ACCA) who has led and worked within finance teams in a
variety of industries, from business advisory groups to medical technology and
pharma companies, to banking. Before SkinBioTherapeutics, Emily was Group Head
of Financial Planning and Analysis at Azets, the international business
advisory group. Prior to this, she held senior finance positions at THF
Holdings, Leica Biosystems, Quantum Pharma, Northumbria University (Faculty of
Health & Life Sciences), Alta Link and Northern Rock. She has a 1st class
BA (Hons) in Accounting from Northumbria University.

 

Martin Hunt, Chairman of SkinBioTherapeutics, said:

"On behalf of the Board, I'm delighted to welcome both Alyson and Emily to the
Board, and congratulate Emily on her promotion. I'd also like to thank Cathy
Prescott for the work she's done as Chair of the Audit Committee and for
Danielle for staying on as an advisor. These appointments strengthen the
Board, especially the financial elements and provide welcome support to the
Executive Management as we enter a busy 2026."

 

-Ends-

 

The following information is disclosed pursuant to rule 17 and Schedule Two
paragraph (g) of the AIM Rules for Companies:

 

 Full name:                                   Alyson Levett
 Age:                                         59
 Shareholding in SkinBioTherapeutics:         Nil
 Current directorships held:                  Eleco plc, NED

                                              GETECH Group plc, NED

                                              En-Fold Autism Support Northamptonshire, Trustee

                                              Financial Services Compensation Scheme, NED

                                              AMTE Power, NED (in administration)
 Directorships held in the previous 5 years:  i-nexus - NED, resigned December 2022

 

 Full name:                                   Emily Bertram
 Age:                                         42
 Shareholding in SkinBioTherapeutics:         Nil
 Current directorships held:                  NA
 Directorships held in the previous 5 years:  NA

 

-Ends-

For more information please contact:

 SkinBioTherapeutics plc                                  +44 (0) 191 495 7325

 Stuart J. Ashman, CEO

Emily Bertram, Group Finance Director
 Singer Capital Markets (Nominated Adviser & Broker)      +44 (0) 020 7496 3000

 Philip Davies

Andrew Johnson

James Todd
 Vigo Consulting (financial press)                        +44 (0) 20 7390 0230

 Rozi Morris, Melanie Toyne-Sewell                        SkinBio@vigoconsulting.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Group's proprietary platform technology, SkinBiotix(®), is based upon
discoveries made by the translational dermatology team at the University of
Manchester.

The Group's foundation business is targeting the skin healthcare market via
five pillars, the most advanced of which are cosmetic skincare
(SkinBiotix(®)) and food supplements that harness the gut-skin axis
(AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where
SkinBiotix(®) is being used as an active skin ingredient with the Croda trade
name, Zenakine™. The AxisBiotix™ pillar has a range of products targeting
the symptoms of inflammatory skin conditions, being sold directly and via
Amazon, and on the High Street in selected Superdrug Stores plc stores.

The Group is also acting as a consolidator and is making acquisitions in
complementary areas such as skincare and cosmetic applications, that also
bring new distribution and geographical platforms, and manufacturing
capabilities through which it can funnel its in-house pillar products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For
more information, visit: www.skinbiotherapeutics.com
(http://www.skinbiotherapeutics.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAKZGGMKDRGVZM



            Copyright 2019 Regulatory News Service, all rights reserved